HBM Healthcare Investments AG

Founded 2001

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 195
Average round size
info
The average size of a deal this fund participated in
$41M
Portfolio companies 115
Rounds per year 9.75
Lead investments 31
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.41
Exits 56
Key employees 4
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

The main office of represented VC is situated in the Zug. The company was established in Europe in Switzerland.

Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Harmony Biosciences, Vivoryon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical, Medical Device. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Besides them, we counted 4 critical employees of this fund in our database.

The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. The typical startup value when the investment from HBM Healthcare Investments AG is 100-500 millions dollars. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this HBM Healthcare Investments AG performs on 3 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the HBM Healthcare Investments AG, startups are often financed by OrbiMed, Kleiner Perkins, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Novartis Venture Fund, Venrock. In the next rounds fund is usually obtained by SV Health Investors, Alta Partners, Maverick Ventures.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ignis Therapeutics

Biotechnology
$180M11 Nov 2021 Shanghai, Shanghai, China

CardiaLen

Biotechnology
Life Science
Medical Device
24 Jun 2021 Minneapolis, Minnesota, United States

NiKang Therapeutics

Biotechnology
Health Care
Medical
$200M26 May 2021 Wilmington, Delaware, United States

Swixx Biopharma

Biopharma
Biotechnology
Life Science
$53M20 May 2021 Zug, Switzerland

Numab

Biopharma
Biotechnology
Health Diagnostics
Life Science
Medical
Therapeutics
$109M19 May 2021 Zurich, Switzerland

Sphingotec GmbH

Biotechnology
06 May 2021 Hohen Neuendorf, Brandenburg, Germany

connectRN

Health Care
Hospital
Marketplace
Medical
Mobile Apps
Nursing and Residential Care
06 Apr 2021 Boston, Massachusetts, United States

Shape Memory Medical

Health Care
Medical Device
Therapeutics
25 Mar 2021 San Jose, California, United States

Biotechnology
Medical
Therapeutics
$95M12 Mar 2021 Basel, Basel-City, Switzerland
News
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

Pyxis Oncology Raises $152M Series B Round

– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent HBM Healthcare Investments AG?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: